Insider Buying: Knight Therapeutics Inc. (TSE:GUD) Insider Buys 17,600 Shares of Stock

Knight Therapeutics Inc. (TSE:GUD) insider Sime Armoyan bought 17,600 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The stock was purchased at an average price of C$5.48 per share, with a total value of C$96,488.48.

Knight Therapeutics Trading Up 0.9 %

TSE GUD opened at C$5.60 on Thursday. Knight Therapeutics Inc. has a 12 month low of C$5.09 and a 12 month high of C$6.23. The company has a debt-to-equity ratio of 7.52, a current ratio of 3.36 and a quick ratio of 1.79. The company has a market capitalization of C$566.44 million, a price-to-earnings ratio of -18.70, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50. The company’s fifty day moving average price is C$5.53 and its two-hundred day moving average price is C$5.56.

Wall Street Analyst Weigh In

Separately, Raymond James upgraded shares of Knight Therapeutics to a “moderate buy” rating in a research note on Friday, November 15th.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.